Hypoprothrombinemia associated with cefoperazone therapy

Rudolph J. Mueller*, David Green, John P. Phair

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Cefoperazone, a β-lactam antibiotic with a methylthiotetrazole side chain, has been reported infrequently to cause hypoprothrombinemia and hemorrhage. We retrospectively analyzed the records of 80 patients who had been given this drug for more than 72 hours. Nine patients received vitamin Ki (phytonadione) prophylaxis and had no evidence of hemorrhage. Of the remaining 71 patients, 32 had prothrombin times measured; 14 of them had hypoprothrombinemia. Prothrombin times ranged from 14.8 to 97.3 seconds at a mean of 6.2 days after initiation of therapy. Seven of the 14 patients had clinically significant hemorrhage and five required transfusions. Two patients with clinically evident hemorrhage died during or immediately after cefoperazone therapy. Prothrombin times rapidly returned to normal in all patients treated with phytonadione. We believe hypoprothrombinemia is a more common complication of cefoperazone therapy than is generally acknowledged, and is preventable.' Unless clinically contraindicated, we recommend that all patients treated with cefoperazone receive phytonadione prophylaxis.

Original languageEnglish (US)
Pages (from-to)1360-1362
Number of pages3
JournalSouthern Medical Journal
Issue number11
StatePublished - Nov 1987

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Hypoprothrombinemia associated with cefoperazone therapy'. Together they form a unique fingerprint.

Cite this